CP smart home AI health services will be launched this year. Guangxi Liuyao Group: The new online settlement policy is conducive to improving the current high accounts receivable situation. | Direct hit earnings conference
At the earnings conference, Chairman Zhu Chaoyang of Guangxi Liuyao Group introduced the progress of the company's AI scenario application business. For the high accounts receivable, the company's CFO Zeng Xiangxing stated that the company has adjusted its operational strategy and strengthened the collection efforts. Guangxi Liuyao Group also responded to the slight decline in growth of the pharmaceutical wholesale sector and issues related to the expansion of pharmaceutical new retail business.
Traditional Chinese medicine health products face difficulties in transitioning online. Shouxiangu Pharmaceuticals: Striving to have top anchors promote products during the singles' day sales. | Earnings conference in focus.
①The demand for traditional Chinese medicine health products has not improved; ②Zhejiang Shouxiangu pharmaceutical is promoting singles' day sales through live streaming hosts; ③Multiple measures are taken to maintain product price stability; ④Online transformation still faces certain challenges.
Livzon Pharmaceutical Group Inc. expects reduced performance pressure in the second half of the year | Live coverage of the earnings conference
① At the results meeting, Yang Liang, director of Lizhu Group, responded to issues such as the year-on-year decline in the company's revenue and financial data in various segments; ② Tang Yanggang, president of the company, said that the overall market size of tocilizumab injections in China is small.
A subsidiary has been "blacklisted" by Shenzhen for one year. Jointown Pharmaceutical Group claims to be "in the process of defending". The industry believes that the intensity of procurement supervision is continuously increasing.
Recently, Jointown Pharmaceutical Group's subsidiary, Jointown Medical Device, was fined and banned from participating in Shenzhen procurement for one year due to providing false information in a tender at a hospital in Shenzhen. Jointown Pharmaceutical Group responded to a reporter from Caijing.com.cn, stating that this incident is a pending matter, and they have organized appeal materials and are currently undergoing administrative reconsideration. This year, several listed companies have been fined for violations in the bidding and procurement process, leading industry insiders to suggest that companies should pay more attention to compliance with details during the bidding process.
Zhejiang Jolly Pharmaceutical: The regions that won the centralized procurement bids have basically achieved volume-based pricing and will develop 10 varieties of Wuling series.
①The company has seen both gains and losses in centralized procurement, for example, sales in centralized procurement areas have increased significantly compared to non-centralized procurement areas, but the company once lost the bid in the procurement of Bacillus Subtilis; ②Due to the reduction of sales expenses and other reasons, the net income of the company in the areas where it won the bid in centralized procurement has actually increased; ③Currently, the company's production capacity utilization rate of Trametes versicolor powder is relatively high and expansion projects for the second phase are underway, with future considerations for planning new production capacity.
Affected by the centralized procurement, yabao pharmaceutical group: the cancellation of product network qualification by hebei has a relatively small impact on profits. | Live coverage of the earnings conference
①The chairman of Yabao Pharmaceutical Group stated that the cancellation of the qualification for several products by Hebei only had a small impact on the profits. ②The sales of H1 Betacismol Hydrochloride Injection decreased under the influence of centralized procurement, leading to a slight decrease in the company's sales revenue. ③Sales of Dinggui Erqin Patch are seasonal, with a slight decrease in revenue in the second quarter.